Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Upgrade Now
Tokyo - Delayed Quote JPY

Oncolys BioPharma Inc. (4588.T)

Compare
532.00
-17.00
(-3.10%)
At close: April 4 at 3:30:00 PM GMT+9
Currency in JPY All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
31,384
63,038
976,182
642,494
314,179
Cost of Revenue
--
32,433
637,695
443,690
78,065
Gross Profit
31,384
30,604
338,487
198,803
236,113
Operating Expense
1,853,752
1,960,591
1,542,993
1,653,357
1,910,766
Operating Income
-1,822,368
-1,929,987
-1,204,506
-1,454,554
-1,674,653
Net Non Operating Interest Income Expense
-18,599
-13,933
-3,388
-15,740
-17,398
Pretax Income
-1,821,270
-1,935,578
-1,146,005
-1,611,714
-2,091,359
Tax Provision
3,340
2,926
2,932
3,725
3,727
Net Income Common Stockholders
-1,824,611
-1,938,505
-1,148,938
-1,615,439
-2,095,087
Diluted NI Available to Com Stockholders
-1,824,611
-1,938,505
-1,148,938
-1,615,439
-2,095,087
Basic EPS
-95.72
-108.92
-66.31
-95.50
-145.58
Diluted EPS
-95.72
-108.92
-66.31
-95.50
-145.58
Basic Average Shares
19,349.41
17,797.36
17,327.41
16,915.15
14,391.62
Diluted Average Shares
20,872.86
17,797.36
17,327.41
16,915.15
14,391.62
Total Operating Income as Reported
-1,822,368
-1,929,986
-1,204,506
-1,454,554
-1,674,652
Total Expenses
1,853,752
1,993,024
2,180,688
2,097,047
1,988,831
Net Income from Continuing & Discontinued Operation
-1,824,611
-1,938,505
-1,148,938
-1,615,439
-2,095,087
Normalized Income
-1,807,793.34
-1,921,791.78
-1,161,996.30
-1,538,548.62
-1,839,892.79
Interest Income
1,989
1,475
587
494
565
Interest Expense
4,006
3,602
3,945
4,169
4,170
Net Interest Income
-18,599
-13,933
-3,388
-15,740
-17,398
EBIT
-1,817,264
-1,931,976
-1,142,060
-1,607,545
-2,087,189
EBITDA
-1,815,119
-1,929,690
-1,141,146
-1,601,059
-2,082,299
Reconciled Cost of Revenue
--
32,433
637,695
443,690
78,065
Reconciled Depreciation
2,145
2,286
914
6,486
4,890
Net Income from Continuing Operation Net Minority Interest
-1,824,611
-1,938,505
-1,148,938
-1,615,439
-2,095,087
Total Unusual Items Excluding Goodwill
-21,898
-21,762
17,003
-110,825
-367,821
Total Unusual Items
-21,898
-21,762
17,003
-110,825
-367,821
Normalized EBITDA
-1,793,221
-1,907,928
-1,158,149
-1,490,234
-1,714,478
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-5,080.34
-5,048.78
3,944.70
-33,934.62
-112,626.79
12/31/2020 - 12/6/2013

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

4565.T Nxera Pharma Co., Ltd.
796.00
-5.35%
 
4587.T PeptiDream Inc.
1,939.50
-3.63%
 
BSLN.SW Basilea Pharmaceutica AG
40.15
-5.97%
 
KLRS Kalaris Therapeutics, Inc.
7.08
-4.32%
 
PRTC PureTech Health plc
17.30
-5.52%
 
SANION.ST Saniona AB (publ)
5.90
-4.38%
 
PHVS Pharvaris N.V.
14.28
-2.33%
 
SEER Seer, Inc.
1.7100
+3.01%
 
OABI OmniAb, Inc.
2.0900
-6.28%
 
SANN.SW Santhera Pharmaceuticals Holding AG
12.86
-10.20%